Month: October 2021

Chemically Defined iCELLis® Bioreactor-Based Viral Vector Manufacturing – Application of Aber Biomass Probes to Inform Transfection Timing

By

Abstract Utilization of classical adherent formats in large scale viral vector manufacturing can have significant setbacks due to the lack of scalability of production vessels typically used at small scale. The iCELLis fixed bed bioreactor has emerged as an enabling technology to efficiently scale adherent-based processes in a controlled and highly integrated environment. This technology …

AAV Production – How To Improve Transfection Efficiency and Titer Yield

By

Production of Adenoviral Associated Viral Vectors   Introduction Adenoviral associated viral (AAV) vectors used in gene therapy have received notable attention considering the recent clinical successes. Traditionally, production of these vectors is achieved by triple transient transfection using the adherent HEK293 cell line in fetal bovine serum (FBS)-supplemented basal media, such as DMEM. The basal …

Blood-Free Fetal Bovine Serum Alternatives in Cell Culture Media

By

An Interview with Marcus Curl, Director of Product Applications Can you start by providing a quick introduction to InVitria and how you provide value to biopharmaceutical manufacturing? InVitria provides an alternative to serum and serum-proteins in the production and formulation of therapeutics. We specialize in creating completely blood component-free manufacturing environments for gene therapy, cell …

Improvement of Vaccine Manufacturing Process with Use of Recombinant HSA Excipient

By

Recombinant Human Serum Albumin Excipient – Regulatory Filing and Approval for Use in Vaccine Manufacturing During the 2020 Excipient World Conference & Expo, supported by IPEC-Americas, Kara Quinn, the Associate Director of Engineering for Merck & Co, presented an online seminar detailing the first-hand account of the complex process of regulatory agency filing that led …